SCHEMBL285262

SCHEMBL285262

Nc1ncnc2c1ncn2[C@H]1CC[C@@H](COP(=O)(O)O)O1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 2/20 0.62
DNPH1 O43598 1/20 0.62
PRKAB2 O43741 1/20 0.62
TRPM2 O94759 1/20 0.62
LDHA P00338 1/20 0.62
ADRB2 P07550 1/20 0.62
FBP1 P09467 1/20 0.62
SRC P12931 1/20 0.62
ADORA1 P30542 1/20 0.62
P2RY2 P41231 1/20 0.62
PRKAG1 P54619 1/20 0.62
PRKAA2 P54646 1/20 0.62
PDE4D Q08499 1/20 0.62
KCNH2 Q12809 1/20 0.62
PRKAA1 Q13131 1/20 0.62
PDE3A Q14432 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
TAS1R3 Q7RTX0 1/20 0.62
TAS1R1 Q7RTX1 1/20 0.62
P2RY11 Q96G91 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20225019 1.00 P2RY1 (0.62) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL18837728 1.00 P2RY1 (0.62) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL20959779 1.00 P2RY1 (0.62) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL20225051 1.00 P2RY1 (0.62) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL19145744 0.93 POLB (0.54) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL23978230 0.92 P2RX3 (0.61) P2RY1TRPM2SRCP2RY2SMN1; SMN2
SCHEMBL31229395 0.92 P2RX3 (0.61) P2RY1TRPM2SRCP2RY2SMN1; SMN2
SCHEMBL4969963 0.92 P2RX3 (0.61) P2RY1TRPM2SRCP2RY2SMN1; SMN2
SCHEMBL21894145 0.92 BCHE (0.53) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL21636992 0.92 POLB (0.53) P2RY1DNPH1PRKAB2TRPM2LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4285463-B1 WIRELESS POWER TRANSMISSION SYSTEMS AND METHODS FOR SELECTIVELY SIGNAL DAMPING FOR ENHANCED COMMUNICATIONS FIDELITY NUCURRENT INC (US) 2025-12-17 EP claimed
CN-116191616-B Wireless charging and discharging adjusting equipment suitable for welding production line 淮阴工学院 2023-10-20 CN claimed
CN-116191616-A Wireless charging and discharging adjusting equipment suitable for welding production line 淮阴工学院 2023-05-30 CN claimed
CN-115438842-A Load prediction method based on adaptive improved dayflies and BP neural network 武汉大学 2022-12-06 CN claimed
WO-2014031954-A1 HOMOPOLYMER MEDIATED NUCLEIC ACID AMPLIFICATION TUFTS UNIVERSITY (US) 2014-02-27 WO claimed
EP-2428201-A1 Oral administration of nucleoside monophosphates Merck Serono S.A. (CH) 2012-03-14 EP claimed
US-6498036-B1 Methods of targeting a chromosomal gene sequence in a eukaryotic cell TRUSTEES OF AMHERST COLLEGE 2002-12-24 US claimed
US-5627165-A ANTIVIRAL AND ANTILEUKEMIA AGENTS DRUG INNOVATION & DESIGN, INC. (US) 1997-05-06 US claimed
EP-0533833-B1 PHOSPHOROUS PRODUGS GLAZIER ARNOLD (US) 1995-12-20 EP claimed
EP-0533833-A1 PHOSPHOROUS PRODRUGS. GLAZIER ARNOLD (US) 1993-03-31 EP claimed
WO-1991019721-A1 PHOSPHOROUS PRODUGS GLAZIER ARNOLD (US) 1991-12-26 WO claimed
US-20260142690-A1 Wireless Power Transfer System With Data Versus Power Priority Optimization NUCURRENT INC (US) 2026-05-21 US disclosed
US-12634614-B2 Wireless power transfer system for wearable communication devices NUCURRENT, INC. (US) 2026-05-19 US disclosed
US-12633782-B2 Software based thermal mitigation for wireless power and data transfer systems NUCURRENT, INC. (US) 2026-05-19 US disclosed
WO-2026098934-A1 AUXILIARY DEVICE FOR CONTROLLING AN ENGINE WITH ELECTROMAGNETICALLY CONTROLLED INJECTORS FR TEAM INTERNATIONAL S.A. (LU) 2026-05-15 WO disclosed
EP-0355135-A1 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1990-02-28 EP disclosed
EP-0350287-A2 Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use NeXstar Pharmaceuticals, Inc. (US) 1990-01-10 EP disclosed
WO-1989004662-A1 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-06-01 WO disclosed
US-4788181-A 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1988-11-29 US disclosed
EP-0284405-A2 Anti-viral compounds, dosage forms and methods BAKER NORTON PHARMACEUTICALS, INC. (US) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12633782-B2 Software based thermal mitigation for wireless power and data transfer systems CRY2, CHRNA2, TRHDE P2RY1 2224/4885DNPH1 3285/4885PRKAB2 56/4885
US-12634614-B2 Wireless power transfer system for wearable communication devices WAPL, ATRIP, ADIPOR1 P2RY1 562/4885DNPH1 4420/4885PRKAB2 173/4885
US-20260142690-A1 Wireless Power Transfer System With Data Versus Power Priority Optimization USE1, SLC18A2, AADAT P2RY1 1610/4885DNPH1 3953/4885PRKAB2 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.